GlassScriptPhysician profile
Abdul Abbasi
NPI 1467408864
$1,820.38
in general payments reported to CMS, 2019-2025
19 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $160 · 2021: $221 · 2022: $405 · 2023: $290 · 2024: $73.83 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $311.30 | 2019-2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $274.20 | 2019-2023 | Brilinta, Farxiga |
| Janssen Pharmaceuticals, INC | $269.39 | 2019-2022 | |
| Pfizer INC. | $246.11 | 2019-2025 | |
| Bard Peripheral Vascular, INC. | $140.94 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $131.59 | 2019-2020 | |
| Cathworks, INC. | $84.12 | 2023 | Ffrangio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.48 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $50.78 | 2020-2024 | |
| Medtronic, INC. | $46.83 | 2023 | Onyx Frontier |
| Irhythm Technologies, INC. | $37.28 | 2024 | Zio Xt Patch, Zio Monitor |
| Astellas Pharma US INC | $36.77 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $27.43 | 2019 | |
| Boston Scientific Corporation | $26.85 | 2022 | |
| Opsens INC. | $20.73 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $17.56 | 2019 | |
| Abbott Laboratories | $16.54 | 2019 | |
| Amarin Pharma, INC. | $13.63 | 2019 | |
| Gilead Sciences, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Abbasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.